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Although several studies have found overexpression of epidermal growth factor receptor (EGFR) proteins EGFR and Her-2 in head
and neck cancers, the clinical relevance of the finding varies. We examined the expression and clinical association of these molecules
with oral squamous cell carcinoma in an area where betel chewing is prevalent. EGFR and Her-2 proteins were measured in 59
paired (grossly normal and cancer) tissues by an enzyme immunoassy method. The cutoff value for gene overexpression was defined
as the level of mean expression in normal tissue plus two s.d. A total of 59% of the patients consumed alcohol, 90% smoked tobacco,
and 90% chewed betel quid. Of the patients assayed, 34 (58%) and 24 (41%) had EGFR and Her-2 overexpression, with average 3.5-
and 1.5-fold elevations. EGFR overexpression has been shown to be statistically associated with T stage, N stage, overall TMN stage,
primary tumour depth, lymph node extra-capsular spread, and poor survival. Her-2 overexpression, however, did not demonstrate a
similar association with clinicopathological parameters or therapeutic outcome. On multivariant analysis, EGFR overexpression
(P¼0.041) and N stage (P¼0.024) were the only independent factors for overall survival. These results indicate that the molecular
targeting therapy to EGFR may be a treatment for oral cavity cancer in the betel quid-chewing prevalent area.
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Squamous cell carcinoma (SCC) of the oral cavity is one of the
most frequent cancers in the world (Vokes et al, 1993). This
disease occurs much more frequently in males (Johnson, 1991).
Epidemiologic studies show a strong association between its
incidence and environmental carcinogens, especially the use of
tobacco, alcohol, and betel quid (Franceschi et al, 1990; Ko et al,
1995; Hsieh et al, 2001). In Taiwan, the incidence of oral carcinoma
is one of the highest in the world. The incidence of oral cavity
cancer was 20 per million in our male population, comprising
approximately 4–5% of all malignancies (Chen, 1987). Approxi-
mately 85% of all oral cavity cancer patients habitually use betel
quid (Chong, 1966). The majority of oral carcinoma in Taiwan
occurs in buccal mucosa (ICD145), which was relatively less
common in Western populations (Daftary et al, 1991). Such
geographical differences in incidence and cancer sites may result
from exposure to different carcinogens, and possibly also from
genetic predisposition.
The overall 5-year survival rate for patients with oral carcinoma
is among the lowest of the major cancers and has not changed
during the past two decades (Parker et al, 1996). The standard
treatment for patients with this cancer is surgery, radiation, or
multiple modalities for patients at high risk (Clayman et al, 1996).
Although standard care is frequently initially successful in early-
stage cancer (stage I or II), disease relapses still occur in about
20–30%, particularly local tumour or lymph node recurrence
(Vikram, 1994; Clayman et al, 1996). For patients with advanced
oral carcinoma (stage III or IV), standard therapy is far less
successful. The recurrent rate in advanced stage is approximately
50–60% and distant metastasis is 20–35% (Clayman et al, 1996).
Even if there is a good treatment response, patients with advanced
disease often suffer substantial functional and cosmetic morbidity,
which decreases the quality of life. The identification of prognostic
factors that may affect disease outcome may lead to improvements
in adjuvant systemic therapy and better control of the disease.
The tyrosine kinase receptor, epidermal growth receptor (EGFR)
family proteins EGFR and Her-2 have been reported to be
overexpressed in many cancers. They are often associated with a
poor prognosis, suggesting that they are potential molecular
targets for anticancer therapy. This family of proteins consists of
four closely related transmembrane receptors, including EGFR
(erbB1), HER-2 (erbB2), HER-3 (erbB3), and HER-4 (erbB-4)
(Olayioye et al, 2000; Simon, 2000). Several ligands, such as EGF
and amphiregulin, bind to EGFR, whereas there is no known high-
affinity ligand binding to Her-2. However, both EGFR and Her-2
interact with other members of the family by heterodimerisation,
resulting in activation of their intrinsic kinase activity (Olayioye
et al, 2000). Overexpression of EGFR and Her-2 have been reported
to be associated with higher grades or reduced survival in a variety
of cancers, including breast, colorectal, and head and neck cancers
(for a review, see Klijn et al, 1992; Salomon et al, 1995). Several
molecular therapeutic agents against EGFR or Her-2, such as
Cetuximab and Herceptin, have been studied in clinical trials
(Colomer et al, 2001; Robert et al, 2002). Received 4 February 2003; revised 13 May 2003; accepted 5 June 2003
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and Her-2 in head and neck cancers, the clinical relevance of the
finding varies. For example, Storkel et al (1993) found that
overexpression of EGFR was associated with shortened survival,
but Werkmeister et al (2000) reported that Her-2 was strongly
associated with survival. Christensen et al (1995) and Khan et al,
(2002) could not find significant correlation of either EGFR or Her-
2 with clinicopathological features or prognosis; however, Bei et al
(2001) and Xia et al (1999) found colocalisation of both molecules
in oral cancer tissues and the combined use of these molecules is a
stronger predictor for the cancer prognosis. We therefore designed
this study to investigate EGFR and Her-2 in paired grossly normal
and cancerous tissues from squamous cell carcinoma of oral cavity
patients. Our aims were to determine their levels of expression and
see if these levels correlated with clinicopathological variables, and
if they were useful prognostically.
MATERIALS AND METHODS
Patients, tissues and cells
Fifty-nine consecutive patients seen in 1999 at the Otorhinolar-
yngology or Head and Neck Surgery clinics at Chang Gung
Memorial Hospital (Taoyuan, Taiwan) were enrolled for the study.
Written informed consent was obtained from all patients
participating in this study. A questionnaire was filled out by each
patient before the first clinical visit investigating whether or not
the patient was a habitual betel net chewer (daily chewer), cigarette
smoker (daily smoker), and/or regular alcohol drinker (daily
drinker). The standard treatment was radical surgery for early-
stage patients and adjuvant radiotherapy for patients with
intermediate risk, such as a close margin or lymph node
metastases. Concomitant chemoradiotherapy was given in patients
with lymph node metastases and extracapsular spread (ECS). All
cancers were histologically graded as well differentiated, moder-
ately differentiated, or poorly differentiated, according to the
World Health Organization (WHO) classification (Shanmugarat-
nam, 1991). For each sample, the presence of bone or nerve
invasion, lymphatics, blood vessels, tumour depth, and the
presence or absence of lymph node ECS were specifically recorded.
Tumour pathological staging was classified according to the AJCC
system (Fleming et al, 1998). Biopsies of cancerous and grossly
normal mucosa tissue were obtained from each subject before
chemo- or radiotherapy. A portion of each tissue sample was
stored in liquid nitrogen until use for molecular assay. An oral
cancer cell line OC2 (Wong et al, 1990) was used as a positive control.
OC2 cells were grown at 37
oC, 5% CO2 in RPMI medium containing
10% fetal bovine serum and antibiotics (100 Uml
 1 penicillin,
100Uml
 1 streptomycin, and 0.25mgml
 1 amphotericin B).
Extraction of cellular proteins
The investigators were blinded as to the source and type of tissue
being assayed. Tissue samples (B50mg) were homogenised in
300ml of a lysis buffer (10mM Tris-HCI, pH 7.5, 1mM MgCl2,1m M
EGTA, 0.5% CHAPS (Pharmacia Ontario, Canada), 10% glycerol,
5m M mercaptoethanol, and 0.1mM phenylmethylsulphonyl fluor-
ide (PMSF) in Kontes tubes with matching pestles rotated at
450r.p.m. After 30min at 41C, the lysate was centrifuged at
15000r.p.m. for 30min at 41C. The supernatants of the protein
extracts were used for the EGFR and Her-2 ELISA assay. The
protein concentration of each tissue sample was determined using
Coomassie protein assay reagent (Pierce).
Determination of EGFR and Her-2 protein levels
An enzyme-linked immunosorbent assay (ELISA) was used to
detect tissue EGFR and Her-2 protein expression. The ELISA kits
were purchased from CalBiochem Inc. (CA, USA). A total of 10mg
cellular protein was used in each assay, performed according to the
manufacturer’s protocol. All samples were analysed in duplicate
and the average of the two was recorded. To define the relative
expression of EGFR or Her-2, both cancer tissue and the normal
counterpart samples were assayed. The cutoff value for gene
overexpression was defined as the level of mean plus two s.d. in the
normal tissue expression values, and was designated as one-fold of
overexpression.
Statistical analysis
The Pearson w
2 test was used to look for the association between
EGFR or Her-2 expression and clinicopathological parameters,
including tumour extent (T, N, and overall stage) and the
pathological findings (degree of differentiation, tumour depth, or
ECS). For prognostic factors analysis, the Kaplan–Meier method
was used for single-variant analysis and the Cox logistic regression
model was used for multivariant analysis. All P-values presented
were two-sided, and the significance level was set at o0.05.
RESULTS
Patient characteristics
The patient characteristics are summarised in Table 1. Their
median age was 48.0 years, ranging from 31 to 78, and all were
male. A total of 59% of the patients consumed alcohol, 90%
smoked tobacco, and 90% chewed betel quid. Cancers included 24
(41%) in the buccal mucosa, 18 (31%) in the tongue, and 17 (29%)
in other sites. All cancers were SCC, with 20 (34%) well
differentiated, 33 (56%) moderately differentiated, and six (10%)
poorly differentiated. The disease staging is summarised in Table 2.
Table 1 Characteristics of patients with oral cancer
Characteristic Number Percentage (%)
Total 59 100
Sex
Female 0 0
Male 59 100
Age
p40 years 13 22
41–60 years 31 53
460 years 15 25
Habits
Alcohol drinking 35 59
Smoking 53 90
Betel quid chewing 53 90
Cancer site
Buccal mucosa 24 41
Tongue 18 31
Others 17 29
Cancer histological grade
Well differentiated 20 34
Moderately differentiated 33 56
Poorly differentiated 6 10
Table 2 Tumour and node stage distribution
Stage T1 T2 T3 T4 Total
N0 7 15 4 11 37
N1 0 2 0 3 5
N2 0 7 5 5 17
Total 7 24 9 19 59
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(25%) had stage II (T2N0), six (10%) had stage III (T3N0, T2N1),
and had 31 (53%) stage IV (T4N0, T4N1, T2N2, T3N2, T4N2).
The distribution of EGFR and Her-2 in oral cancer tissues
The relative expression of EGFR and Her-2 in all 59 patients were
examined and plotted in Figure 1. Similar results were obtained
when we assayed EGFR and Her-2 levels using different sites of the
same tumour. As shown in the Figures, EGFR was overexpressed in
two (3%) normal mucosa tissues and 34 (58%) cancer tissues.
Similarly, Her-2 was overexpressed in one (2%) normal tissue and
24 (41%) cancer tissues. Compared to all normal samples, the
average expression of EGFR in cancer tissue was 3.48-fold, with an
s.d. of 2.01, while the average expression of Her-2 was 1.51-fold,
with an s.d. of 0.45. Thus, although the levels of both EGFR and
Her-2 expression differed significantly between normal and cancer
tissues (Po0.001), EGFR had greater overexpression than Her-2
on average in all the cancer patients. The distribution of EGFR and
Her-2 expression in the 59 oral cancer tissues is summarised in
Table 3. Of the patients, 17 (29%) had normally expressed in both
molecules, 16 (27%) had overexpressed in both molecules, and 26
(44%) had overexpressed in either molecule. EGFR and Her-2 were
not significantly coexpressed (P¼0.245).
Correlation of EGFR or Her-2 with clinicopathological
parameters
The correlations of the expression levels of EGFR or Her-2 with
clinicopathological parameters are shown in Table 4. As shown in
the table, significant correlations were found between EGFR
expression and tumour extent (T stage) (P¼0.010), lymph node
status (N stage) (P¼0.019), clinical overall stage (P¼0.002),
tumour depth (P¼0.035), and ECS of lymph node (P¼0.025).
However, there was no association between Her-2 expression with
cancer stage or any other clinicopathological parameters. The
results indicate that EGFR has an association with the aggressive-
ness of oral cancer.
Evaluation of possible prognostic factors associated with
oral cancer
As shown in Table 5, for the 2-year survival, there were significant
correlations with N stage (P¼0.000), overall stage (P¼0.008),
tumour depth (P¼0.002), ECS of lymph node (P¼0.000), and the
expression levels of EGFR (P ¼0.001). To define the role of the
above factors further, multivariant analysis was conducted and has
been demonstrated in Table 6. Lymph node metastasis (P¼0.024)
and overexpression of EGFR (P¼0.041) were the only independent
variables associated with poor survival, with a risk ratio of 4.22 for
lymph node metastasis (95% CI¼1.21–14.74), and 5.88 for EGFR
overexpression (95% CI¼1.07–32.31). The Kaplan–Meier overall
survival curves related to EGFR overexpression are shown in the
Figure 2.
DISCUSSION
In our study, we found EGFR and Her-2 to be differentially
expressed in oral SCC. Consistent with other reports, we found that
both EGFR and Her-2 were overexpressed in a subset of oral
cancer patients (58 and 41%, respectively). However, compared to
Her-2, EGFR overexpression was more significant in terms of the
expression level (3.5-fold vs 1.5-fold). Although these two
molecules were coexpressed in some patients, this was not a
statistically significant association (P¼0.245). A high level of
EGFR, but not of Her-2, was strongly associated with tumour
aggressiveness and poor survival.
Although some of our findings are consistent with other reports,
we noted above the conflicting data produced by various authors.
These differences may be due to differences in assay techniques.
For example, most of the investigators used the immunohisto-
chemistry method to examine protein expressions (Storkel et al,
1993; Xia et al, 1999; Bei et al, 2001; Khan et al, 2002), while we
used the ELISA method to quantitatively analyse EGFR and Her-2
protein levels. The advantage of the immunohistochemistry
method is the precise localisation of the protein molecules in
cells. However, this method reported that data determined by
microscopic examination may be influenced by the subjective
assessment through different individuals. Although the ELISA
technique is less used in clinical study, this method is also widely
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Figure 1 Relative expression of Her-2 and EGFR. (A) Relative
expression of EGFR (A) and Her-2 (B) in normal and cancer tissue
samples. The horizontal bar in the figure indicates the cut-off value
(designated as one-fold)
Table 3 EGFR and Her-2 overexpression in oral cancer tissues
EGFR overexpression
Her-2 overexpression No Yes Total
No 17 18 35
Yes 8 16 24
Total 25 34 59
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using this technique in the studies of breast cancer, cervical cancer,
lung cancer as well as head and neck cancer (Christensen et al,
1995; Pfeiffer et al, 1998; Contreras et al, 2002; Widschwendter
et al, 2002). The key advantage of the ELISA method is to provide a
quantitative result with relatively less bias. When comparing these
two methods, Pfeiffer et al (1998) have reported that significant
correlation was found in the quantification of EGFR or Her-2 levels
between ELISA and immunohistochemical methods studied in the
lung and in breast cancers. These studies suggest that comparable
evaluation results may be obtained by using these two assay
techniques.
Patient sampling is another variable between other studies and
ours. Most investigators examine protein expressions between
different tumour tissues (but no grossly normal counterpart
tissues to compare) (Storkel et al, 1993; Xia et al, 1999; Bei et al,
2001; Khan et al, 2002). We analyse EGFR and Her-2 protein levels
in the paired grossly normal mucosa and cancer tissues obtained
from the same patients. These results will provide clearer
information regarding the protein level changes after cellular
transformation. Additionally, most other reports have evaluated
populations in the West (Xia et al, 1999; Werkmeister et al, 2000;
Bei et al, 2001), whereas ours focused on Southeast Asians. Since
both carcinogen exposure (including betel quid chewing) and
possible genetic predisposition vary between different geographic
areas, the reported differences in EGFR or Her-2 expression
may reflect different oral carcinogenic pathways in different
populations.
Table 4 Association of EGFR and Her-2 status with clinicopathological parameters
EGFR overexpression Her-2 overexpression
Parameter N No(%) Yes(%) P-value No(%) Yes(%) P-value
T stage
T1–T2 31 18 (58) 13 (42) 0.010 17 (55) 14 (45) 0.461
T3–T4 28 7 (25) 21 (75) 18 (64) 10 (36)
Nstage
N¼0 37 20 (54) 17 (46) 0.019 22 (60) 15 (41) 0.978
N40 22 5 (23) 17 (77) 13 (59) 9 (41)
Overall stage
I–II 22 15 (68) 7 (32) 0.002 12 (55) 10 (46) 0.565
III–IV 37 10 (27) 27 (73) 23 (62) 14 (38)
Differentiation
Well 20 9 (45) 11 (55) 0.852 13 (65) 7 (35) 0.050
Moderate 33 13 (39) 20 (60) 16 (49) 17 (52)
Poor 6 3 (50) 3 (50) 6 (100) 0 (0)
Tumour depth410mm
No 26 15 (58) 11 (42) 0.035 13 (50) 13 (50) 0.196
Yes 33 10 (30) 23 (70) 22 (67) 11 (33)
ECS of lymph node
No 43 22 (51) 21 (49) 0.025 25 (58) 18 (42) 0.762
Yes 16 3 (19) 13 (81) 10 (66) 6 (38)
Total 59 25 (42) 34 (58) 35 (59) 24 (41)
Table 5 Univariant analysis of prognostic factors in oral cancer
Parameter Group
2-year survival
(week) P-value
T stage T1-2/T3-4 73/22 0.101
N stage N0-1/N2-3 80/22 o0.001
Overall stage I–II/III–IV 86/51 0.008
Tumour depth(mm) p10/410 84/48 0.002
LN ECS No/yes 79/19 o0.001
EGFR overexpression ( )/(+) 88/45 0.001
Her-2 overexpression ( )/(+) 64/62 0.928
Table 6 Multivariant analysis of prognostic factors in oral cancer
Parameter Risk ratio 95% CI
a P-value
T stage 0.781 0.22–2.36 0.583
N stage 4.215 1.21–14.74 0.024
Overall stage 0.601 0.009–4.16 0.606
Tumour depth 3.854 0.87–17.16 0.077
ECS of lymph node 1.083 0.52–3.07 0.601
EGFR overexpression 5.882 1.07–32.31 0.041
Her-2 overexpression 1.083 0.36–3.26 0.888
aCI¼confidence interval.
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Figure 2 Kaplan–Meier overall survival curves according to EGFR
overexpression.
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mucosa surface to the same carcinogens or stimulants (such as
alcohol or cigarettes) may lead to a multitude of somatic changes
that are susceptible to the development of multiple primary
cancers. This phenomenon is called ‘field cancerisation’ (Slaughter
et al, 1953). Recent molecular studies have shown that genetical
alterations could be found in different areas of histological
normal mucosa. Examples are mutations of the p53 tumour
suppressor gene and deletions on the short arm of chromosome 3
(Li et al, 1994; Van Dyke et al, 1994). In our grossly normal
mucosa tissues, which provide an internal control for comparing
them with cancer tissues in the same patient, they may not
represent true normal samples, particularly in patients who drink,
smoke, and chew betel quids. However, in our present study, there
is no statistical difference of the protein expression levels of EGFR
and Her-2 between the normal tissues from patients with or
without exposure to tobacco, alcohol, betel quid, or the combined
exposure (data not shown). These results suggest that the ‘filed’
effect of EGFR and Her-2molecules on the surrounding oral
normal mucosa is minimum. Apparently, together with multiple
injuries and cellular genetic mutations on a specific tissue, a
process described as ‘multistep carcinogenesis’ will eventually
transform the cell into malignant cancer (Vogelstein et al, 1998).
For a molecule to be a good candidate as a target for anticancer
therapy, several criteria must be fulfilled. First, the protein should
be overexpressed in cancer tissues compared to normal tissues.
Second, overexpression of the protein should be associated with a
poor prognosis, which suggests that manipulation of the protein
may result in alteration of the prognosis. In this study, we found
that the membrane protein EGFR had both these characteristics.
Our results do not support similar targeting of the Her-2 protein,
even though it is commonly overexpressed in oral SCC. Recently,
targeting of EGFR as a molecular adjuvant therapy has been
clinically tried in head and neck cancer (Shin et al, 2001; Robert
et al, 2002). This study provides a fundamental knowledge base,
suggesting that targeting this molecule might be useful in betel
quid-associated oral cancers (Shin et al, 2001).
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